Sugi Predict

Sugi Predict / Compounds / SCHEMBL463976

SCHEMBL463976

SCHEMBL463976

CCCC(N)C(=O)C(=O)NC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP1 P53582 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ DPP4 P27487 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ SMYD3 Q9H7B4 1/20 0.37
▸ MME P08473 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ EPHX1 P07099 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GRIK1 P39086 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840614 1.00 METAP1 (0.45) METAP1SMN1; SMN2RAB9AGAADPP4
SCHEMBL13274393 1.00 METAP1 (0.45) METAP1SMN1; SMN2RAB9AGAADPP4
Hydrochloric Acid SCHEMBL27922164 0.98 METAP1 (0.44) METAP1SMN1; SMN2RAB9AGAADPP4
Hydrochloric Acid SCHEMBL27922161 0.98 METAP1 (0.44) METAP1SMN1; SMN2RAB9AGAADPP4
Formic Acid SCHEMBL27923729 0.94 METAP1 (0.41) METAP1SMN1; SMN2RAB9AGAADPP4
SCHEMBL463987 0.93 SMN1; SMN2 (0.44) METAP1SMN1; SMN2RAB9AGAADPP4
SCHEMBL15219637 0.92 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL28814747 0.92 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL904231 0.90 METAP1 (0.58) METAP1SMN1; SMN2RAB9AGAADPP4
SCHEMBL15623642 0.90 METAP1 (0.58) METAP1SMN1; SMN2RAB9AGAADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281456-A1 METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS UNIVERSITY OF MARYLAND, BALTIMORE 2025-09-11 — — US disclosed
CN-104293844-B A kind of synthetic method of Telaprevir intermediate 苏州永健生物医药有限公司 2017-10-10 — — CN disclosed
CN-103342736-B A kind of synthetic method of VX-960 SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) 2016-02-10 — — CN disclosed
CN-103342736-B A kind of synthetic method of VX-960 SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) 2016-02-10 — — CN disclosed
CN-103342656-B Synthesis method of Telaprevir intermediate SUZHOU UUGENE BIOPHARMA CO LTD 2015-04-08 — — CN disclosed
CN-104293844-A Synthetic method of telaprevir intermediate SUZHOU UUGENE BIOPHARMA CO LTD 2015-01-21 — — CN disclosed
CN-103946213-A Novel pyrrolidine derivatives as inhibitors of cathepsin HOFFMANN LA ROCHE 2014-07-23 — — CN disclosed
CN-103342656-A Synthesis method of Telaprevir intermediate SUZHOU UUGENE BIOPHARMA CO LTD 2013-10-09 — — CN disclosed
CN-103342736-A Synthesis method of telaprevir SUZHOU UUGENE BIOPHARMA CO LTD 2013-10-09 — — CN disclosed
CN-103342736-A Synthesis method of telaprevir SUZHOU UUGENE BIOPHARMA CO LTD 2013-10-09 — — CN disclosed
US-20100174077-A1 Processes and intermediates VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-08 — — US disclosed
EP-1934179-B1 PROCESSES AND INTERMEDIATES VERTEX PHARMA (US) 2010-04-07 — — EP disclosed
WO-2009152474-A2 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-12-17 — — WO disclosed
US-20090312571-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES VIROBAY, INC. (US) 2009-12-17 — — US disclosed
WO-2008106139-A1 INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 — — WO disclosed
WO-2008106058-A2 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 — — WO disclosed
WO-2008074035-A1 HCV PROTEASE INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2008-06-19 — — WO disclosed
EP-1878720-A1 Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors Vertex Pharmaceuticals Incorporated (US) 2008-01-16 — — EP disclosed
WO-2007133865-A2 HCV/HIV INHIBITORS AN THEIR USES NOVARTIS AG (CH) 2007-11-22 — — WO disclosed
WO-2007025307-A2 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281456-A1 METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS DCK, DTYMK, POLK METAP1 2262/4885SMN1; SMN2 3743/4885RAB9A 3434/4885
US-20100174077-A1 Processes and intermediates TFPI, SPINT2, SERPINB1 METAP1 54/4885SMN1; SMN2 3788/4885RAB9A 2733/4885
US-20090312571-A1 PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES HCN3, NPEPPS, HACL2 METAP1 1957/4885SMN1; SMN2 3506/4885RAB9A 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.